- Conditions
- Postoperative Pain
- Interventions
- HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 22
- States / cities
- Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Autism Disorder
- Interventions
- STX209 (15mg), placebo, STX209 (30mg)
- Drug
- Lead sponsor
- Timothy Roberts
- Other
- Eligibility
- 14 Years to 17 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Parkinson's Disease, Small Intestinal Bacterial Overgrowth
- Interventions
- Rifaximin, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma
- Interventions
- AL58805, AL3818, Temozolomide (TMZ), CCNU
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Brain Cancer, Cancer
- Interventions
- Pembrolizumab, Nab paclitaxel, Paclitaxel, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- John L. Villano, MD, PhD
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
- Interventions
- Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus
- Interventions
- KZR-616
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Upland, California • Miami, Florida + 12 more
- Conditions
- Hemophilia A
- Interventions
- GreenGene™ F and an approved recombinant Factor VIII product, GreenGene™ F
- Biological
- Lead sponsor
- Green Cross Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Torrance, California + 7 more
- Conditions
- Rosacea, Papulopustular Rosacea
- Interventions
- 1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel
- Drug · Other
- Lead sponsor
- Hovione Scientia Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 23
- States / cities
- Bryant, Arkansas • Rogers, Arkansas • Fremont, California + 17 more
- Conditions
- Smoking Cessation, Cigarette Smoking, Smoking (Tobacco) Addiction
- Interventions
- Nicotine Film
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Neoplasms
- Interventions
- TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Taletrectinib, Placebo
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- teplizumab, Placebo
- Biological
- Lead sponsor
- Provention Bio, Inc.
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 34
- States / cities
- San Diego, California • San Francisco, California • Walnut Creek, California + 30 more
- Conditions
- Photoaging, Wrinkle
- Interventions
- Radiofrequency Microneedling, Facial Cleanser, Facial Moisturizer, Sunscreen
- Procedure · Other
- Lead sponsor
- Revision Skincare
- Industry
- Eligibility
- 35 Years to 65 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
- Interventions
- brentuximab vedotin, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 27
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 23 more
- Conditions
- Type 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity
- Interventions
- Study A: Single use of cannabis flower product, Study B: Ad libitum cannabis use for four weeks or no cannabis use
- Other
- Lead sponsor
- University of Colorado, Boulder
- Other
- Eligibility
- 21 Years to 40 Years
- Enrollment
- 233 participants
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Healthy Volunteer
- Interventions
- PTI-428, Placebo, ethinyl estradiol and levonorgestrel
- Drug · Other
- Lead sponsor
- Proteostasis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Metastatic Colon Cancer, Stage III Colon Cancer
- Interventions
- FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol, Encorafenib/Binimetinib/Cetuximab Protocol, Trastuzumab + Pertuzumab
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Malaria
- Interventions
- AQ-13, Chloroquine (CQ) Treatment
- Drug
- Lead sponsor
- Tulane University Health Sciences Center
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Stigma
- Interventions
- point of view simulation, Control
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Obesity
- Interventions
- Semaglutide Injectable Product (not provided by the study)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Moderate-to-severely Painful Ankle Surgery
- Interventions
- Popliteal nerve block including liposomal bupivacaine, Adductor canal nerve block including liposomal bupivacaine, Continuous popliteal nerve block with normal saline, Popliteal nerve block with exclusively unencapsulated bupivacaine, Adductor canal nerve block with exclusively unencapsulated bupivacaine, Continuous popliteal nerve block with unencapsulated bupivacaine
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985, Vic-trastuzumab Duocarmazine, Metastatic Cancer, Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic, HER2 Low Breast Cancer, GastroEsophageal Cancer, Gastroesophageal Adenocarcinoma, Endometrium Tumor, Ovarian Cancer, Ovarian Carcinoma, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2 Low HR Positive, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Bladder Cancer
- Interventions
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado